Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)

Model scores of the 29,894 trials active now.

Model score 14% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10% (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: carcinomacellgemcitabinecancerchemotherapy
  Phrases that lowered it: and safetyefficacy andthe efficacysafety ofwithin weeks
• Collaborators: 3 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 20 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 18.5% (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor's past trials: 10 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment NCT05517239 · started 2015 · scored riskier than 28% of active trials completed
• A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer NCT00872014 · started 2009 · scored riskier than 38% of active trials completed
• Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer NCT00699374 · started 2008 · scored riskier than 18% of active trials terminated
• Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study NCT05117957 · started 2022 · scored riskier than 58% of active trials completed
• Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma NCT02425605 · started 2014 · scored riskier than 56% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.